GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it will host a Key Opinion Leader (KOL) call on June 4, 2021 from 8:00 am to 9:00 am EDT. The webinar will feature presentations by KOLs José-Alain Sahel, MD (University of Pittsburgh School of Medicine) and Botond Roska, MD, PhD (Institute of Molecular and Clinical Ophthalmology Basel), who will discuss the Nature Medicine Case Report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP)., The subject is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. Following the formal presentations, Drs. Sahel and Roska will be available to answer questions.
In addition, GenSight’s management team will discuss highlights from the Nature Medicine Case Report and provide an update on their pipeline candidate, GS030. Administered via intravitreal injection, GS030 uses an optimized viral vector (GS030-DP) to express the light-sensitive opsin ChrimsonR in retinal ganglion cells and proprietary light-stimulating goggles (GS030-MD) to project the right wavelength and intensity of light onto the treated retina.
The webinar will be webcast live at https://bit.ly/3uzvG1j. You will need to register in advance to get access to the webinar. For those unable to attend the live broadcast, a recording will be accessible using the same link.
The Nature Medicine Case Report can be found at https://www.nature.com/articles/s41591-021-01351-4. A video of the patient performing the tests, which was submitted as supplementary material to the publication, can be viewed at www.gensight-biologics.com
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
